China releases therapeutic effect of first COVID-19 oral drug | 首个国产新冠口服药科学研究出炉
时间:2022-08-13 12:19:44
A report on the therapeutic effect of China’s first COVID-19 oral drug VV116 was released Tuesday.
It concluded that confirmed patients receiving the drug within five days of their first positive test saw better treatment results.
The study led by Zhang Wenhong, head of the infectious disease department at Fudan University's Huashan Hospital in Shanghai, and Fan Xiaohong from the Shanghai Public Health Clinical Center, has evaluated the therapeutic effect of VV116 for non-severe cases of the Omicron variant. The research paper was published Tuesday in the magazine Emerging Microbes Wild Infections.
In this study, 136 COVID-19 patients were divided into two groups. Sixty patients in one group took 30 milligrams of VV116 every 12 hours, while the remaining 76 in the control group didn’t receive VV116. Both groups accepted symptomatic treatment, including anti-inflammation.
Data shows that participants who received VV116 within five days of the first positive test had a shorter viral shedding time than the control group (8.56 vs 11.13 days).
Participants who received VV116 after five days ftom the first positive test needed 11.46 days to get a negative result. The control group needed 11.13 days, so there was basically no difference.
Studies on Molnupiravir and Paxlovid, two oral antiviral treatments authorized to treat mild to moderate COVID-19, also showed this rule, backing up the conclusion of earlier treatments and intervention.
The study also collected drug safety data of VV116, and the results showed that there were no serious adverse events.
Source: Ecns.cn
Editor: Gao Xin
Senior Editor: Tian Minjia
深圳早泄阳痿治疗医院苏州男科医院哪家专业
北京眼科检查哪家医院好
洛阳早泄阳痿治疗哪家好
唐山看妇科哪里好
- .比亚迪携三款电动车型亮相巴黎车展 录影公布重大决策
- .昭衍新药(06127)拟每10股转增4股派断定金红利4元
- .乒乓球总决赛:国乒三人出局!男单4强诞生,王楚恭3-0胜张本智和
- .5.59万欧元起,萨多韦PHEV(Coffee 01)欧洲上市,全球化进程再加速
- .天润乳业(600419.SH)发布2022年业绩 净利润1.97亿元 工业产值增31.33% 每10股派1.87元
- .乒乓球总决赛:恩斯打疯了!3-0横扫世界亚军,韩国队全军覆没
- .蔚来ET7有对手了?岚图首款敞篷车定名“追光” 低趴范儿十足
- .蜀道装备(300540.SZ)释出2022年度业绩,净亏损2510万元
- .3-1!王楚钦送欧洲各国冠军回家,1/4决赛战张本智和,国乒首日5胜1负
- .这项国际标准,为何由中国联席?
- .探路者(300005.SZ)拟3852.02万美元母公司芯片设计公司 G2 Touch 72.79%股权
- .张本智和不敌王楚钦,绝地反击还是继续自觉,四强之争上演
- .电动车更难停车?可能不是想象|技术流
- .亿和控股(00838.HK):2022年纯利回升32.8%至2.06亿港元
- .3-0!王楚钦横扫张本智和,男单四强正式稍晚,国乒独揽3席
- .VinFast将解职近1/3已售电动汽车
- .复星医药(02196):FCN-159片获批开展相关制剂的II期临床试验
- .3-2张本聪和振臂欢呼,首秀逆转男乒世界冠军,坐等王楚钦来战!
- .9月动力电池:中都创新航,患上IPO后遗症
- .东胜智慧城市服务(00265)公布本年业绩,溢利2792万港元 同比亏转盈